Skip to main content
. 2018 Nov 16;31(3):393–402. doi: 10.1097/MEG.0000000000001304

Fig. 3.

Fig. 3

Decrease of steatosis, NASH, and fibrosis biomarkers in the selonsertib trial. (a–d) SteatoTest-2 decrease by −0.02 versus +0.04 (P=0.03), SteatoTest −0.014 versus +0.014 (P=0.02), NashTest-2 −0.06 versus +0.01, and FibroTest −0.02 versus +0.02 (P=0.04), in patients who improved NAS versus those who did not improved at 24 weeks.